Castle Biosciences

244 articles with Castle Biosciences

• Castle Biosciences Named in Inc.’s First-Annual Best-Led Companies

  11/17/2021

  Castle Biosciences, Inc. today announced that it has been named in Inc.’s first-annual Best-Led Companies list, a select, data-driven list of the very strongest U.S. firms with revenue of $50 million to $2 billion.

• Castle Biosciences Named a 2021 Houston Chronicle Top Workplace

  11/15/2021

  Castle Biosciences Named a 2021 Houston Chronicle Top Workplace

• Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

  11/10/2021

  Castle Biosciences, Inc. announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, Nov. 18, 2021, at 9:30 a.m. Eastern time.

• Castle Biosciences Announces Third Quarter 2021 Results

  11/8/2021

  Castle Biosciences, Inc., a company applying innovative diagnostics to inform disease management and improve patient outcomes, announced its financial results for the third quarter and nine months ended Sept. 30, 2021.

• Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report

  11/8/2021

  Castle Biosciences, Inc. today announced the launch of the Company’s inaugural Environmental, Social and Governance (ESG) report, detailing the Company’s related policies and metrics.

• Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm

  11/5/2021

  Castle Biosciences, Inc today announced the publication of a study validating performance of a novel algorithm designed to integrate the DecisionDx®-Melanoma gene expression profile

• Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System

  11/4/2021

  Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA ® Electronic Health Records System

• DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence

  10/28/2021

  Castle Biosciences, Inc. today announced that the DecisionDx®-Melanoma integrated test result (ITR) now includes i31-GEP for Risk of Recurrence (i31-ROR).

• New Data Demonstrating Accuracy of DecisionDx® DiffDx™-Melanoma Presented at ASDP 58th Annual Meeting

  10/26/2021

  New Data Demonstrating Accuracy of DecisionDx ® DiffDx ™ -Melanoma Presented at ASDP 58th Annual Meeting

• Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021

  10/25/2021

  Castle Biosciences, Inc. today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2021, after the close of market on Monday, Nov. 8, 2021.

• Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021

  10/22/2021

  Castle Biosciences, Inc. today announced recent poster presentations on the Company’s suite of dermatologic cancer gene expression profile (GEP) tests, as well as a poster describing the study design for its inflammatory skin disease pipeline initiative at the 2021 Fall Clinical Dermatology Conference, held Oct. 21-24.

• 

  Biopharma News You've Missed This Week

  10/20/2021

  More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.

• Castle Biosciences to Acquire Cernostics

  10/19/2021

  Castle Biosciences, Inc. today announced it has signed a definitive agreement to acquire Cernostics, Inc. (Cernostics), an Illumina Ventures company.

• Castle Biosciences President and CEO Derek Maetzold Will Deliver Keynote Presentation During Arizona Bioscience Week

  9/28/2021

  Castle Biosciences, Inc. today announced that Derek Maetzold, president and chief executive officer, will deliver the keynote presentation during Arizona Bioscience Week, taking place from Oct. 3-9, 2021.

• Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma

  9/16/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to improve treatment decisions, announced that it has received approval from the New York State Department of Health for its proprietary DecisionDx® DiffDx™-Melanoma gene expression profile test.

• Castle Biosciences Recognized as a Top 100 Healthcare Technology Company of 2021

  8/30/2021

  Castle Biosciences, Inc. today announced that it has been included in The Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2021 list.

• Castle Biosciences to Present at Upcoming Investor Conferences - Aug 26, 2021

  8/26/2021

  Castle Biosciences, Inc. announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the following upcoming investor conferences:

• Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

  8/24/2021

  Castle Biosciences, Inc. today announced that it has been awarded a five-year U.S. Federal Supply Schedule (FSS) contract from the Veterans Health Administration (VHA) for its DecisionDx®-Melanoma gene expression profile test.

• Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting

  8/16/2021

  Castle Biosciences, Inc. today announced recent presentations on two of its skin cancer gene expression profile tests at the 2021 American Academy of Dermatology (AAD) Summer Meeting, held Aug. 5-8, 2021.

• Castle Biosciences Announces Second Quarter 2021 Results

  8/9/2021

  Castle Biosciences, Inc. today announced its financial results for the second quarter and six months ended June 30, 2021.